Brief: NKGen Biotech Announces Clearance Of Clinical Trial Application By Health Canada For SNK01 NK Cell Therapy
27/12/2023 13:41
Dec 27 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH ANNOUNCES CLEARANCE OF CLINICAL TRIAL
APPLICATION
BY HEALTH CANADA FOR SNK01 NK CELL THERAPY TO TREAT ALZHEIMER’S
DISEASE
* NKGEN BIOTECH: APPROVED TRIAL OF ABOUT 36 PATIENTS WITH
MODERATE
AD IS EXPECTED TO COMMENCE IN DECEMBER 2023 WITH FIRST INTERIM
DATA EXPECTED IN Q3 2024
Source text for Eikon: ID:nGNX3zbqv0
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program